Candida sp. infections in patients with Diabetes mellitus by Rodrigues, Célia F. et al.
  
J. Clin. Med. 2019, 8, 76; doi:10.3390/jcm8010076 www.mdpi.com/journal/jcm 
Review 
Candida sp. Infections in Patients with Diabetes 
Mellitus 
Célia F. Rodrigues 1,2,*, Maria Elisa Rodrigues 1 and Mariana Henriques 1 
1 CEB, Centre of Biological Engineering, LIBRO-Laboratório de Investigação em Biofilmes Rosário Oliveira, 
University of Minho, 4710-057 Braga, Portugal; elisarodrigues@deb.uminho.pt (M.E.R.); 
mcrh@deb.uminho.pt (M.H.) 
2 LEPABE—Department of Chemical Engineering, Faculty of Engineering, University of Porto,  
Rua Dr. Roberto Frias, s/n, Porto, 4200-465, Portugal 
* Correspondence: c.fortunae@gmail.com; Tel.: +351 22 041 4859 (C.F.R.) 
Received: 14 December 2018; Accepted: 3 January 2019; Published: 10 January 2019 
Abstract: Candidiasis has increased substantially worldwide over recent decades and is a significant 
cause of morbidity and mortality, especially among critically ill patients. Diabetes mellitus (DM) is 
a metabolic disorder that predisposes individuals to fungal infections, including those related to 
Candida sp., due to a immunosuppressive effect on the patient. This review aims to discuss the latest 
studies regarding the occurrence of candidiasis on DM patients and the pathophysiology and 
etiology associated with these co-morbidities. A comprehensive review of the literature was 
undertaken. PubMed, Scopus, Elsevier’s ScienceDirect, and Springer’s SpringerLink databases were 
searched using well-defined search terms. Predefined inclusion and exclusion criteria were applied 
to classify relevant manuscripts. Results of the review show that DM patients have an increased 
susceptibility to Candida sp. infections which aggravates in the cases of uncontrolled hyperglycemia. 
The conclusion is that, for these patients, the hospitalization periods have increased and are 
commonly associated with the prolonged use of indwelling medical devices, which also increase 
the costs associated with disease management. 
Keywords: Candida; biofilms; diabetes; medical devices; candidiasis; metabolic disorder; 
hyperglycemia; infection 
 
1. Introduction 
Diabetes mellitus (DM) is a chronic metabolic and degenerative disorder that is characterized by 
chronic hyperglycemia and causes long-term complications like retinopathy, neuropathy, and 
nephropathy, generally accelerating macro- and micro-vascular changes. It is becoming one of the 
largest emerging threats to public health in the 21st century[1,2]. Several immune alterations have 
been described in diabetes with cellular immunity being more compromised and with changes in 
polymorphonuclear cells, monocytes, and lymphocytes[3]. DM individuals have higher glucose 
serum concentrations than healthy individuals (between 4.0 to 5.4 mmol/L or 72 to 99 mg/dL when fasting 
and up to 7.8 mmol/L or 140 mg/dL two hours after eating [4]; hemoglobin A1c (glycohemoglobin) ≤5.7%). 
In type 1 DM, the pathogenesis is multifactorial because of antibody-mediated autoimmunity, 
environmental toxins exposure, and major histocompatibility complex (MHC) Class II 
histocompatibility complex HLA-DR/DQ genetic polymorphisms. These features create an increased 
susceptibility to disease onset due to a continuous loss of insulin-producing β-cells in the pancreas, 
which is due to the T-cells’ infiltration through mitochondrial-driven apoptosis[5]. On the other hand, 
in type 2 DM, there is an insulin resistance that is associated with changes in the mitochondrial 
metabolism with reduced mitochondrial density, ATP production, and mitochondrial RNA (mtRNA) 
levels, as well as increased markers for oxidative stress. The chronic exposure of the circular mtDNA 
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to these effects might trigger significant tissue modifications found in the pancreas and endothelial 
cells, leading to secondary vascular disease and causing cardiac, renal, ophthalmic, and neurological 
complications[5–7] (Figure 1). 
 
Figure 1. Main diseases related to Candida sp. occurring with higher incidence in patients with 
diabetes mellitus type 1 or type 2 (adapted image from GraphicsRF on stock.adobe.com). 
In 2017, the worldwide prevalence of adult-onset diabetes (20–79 years) was nearly 425 million, 
and the World Health Organization and the International Diabetes Federation predicted that the 
number of adults in the world with diabetes will rise near 629 million by the year 2045[8,9] (Figure 2). A 
higher prevalence of DM, cardiac, and pulmonary diseases can be found in senior patients with 
candidemia [10–13]. The relationship between diabetes and candidiasis has been widely studied [13–16], 
particularly due to the increased susceptibility of diabetic patients to fungal infections compared to 
those without DM [14,15,17,18]. 
Several mechanisms are attributed to higher Candida sp. predisposition among DM patients 
depending on the local or systemic infection. Among the recognized host conditions for candidal 
colonization and subsequent infection are yeast adhesion to epithelial cell surfaces[19], higher 
salivary glucose levels[15,20], reduced salivary flow[21], microvascular degeneration, and impaired 
candidacidal activity of neutrophils. These conditions are particularly serious in the presence of 
glucose[22,23], secretion of several degradative enzymes[24–26], or even a generalized 
immunosuppression state of the patient[8,27–31]. These factors have a major influence on the balance 
between host and yeasts, favoring the transition of Candida sp. from commensal to pathogen and 
causing infection. In fact, in a very recent study, Gürsoy et al.[32] suggested that there is a higher 
presence of intestinal Candida albicans colonization in diabetic patients. In fact, there may be a 
tendency of type 1 DM in patients with a high prevalence of intestinal C. albicans. C. albicans is also 
known to wait for a change in some aspect of the host physiology that normally suppress growth and 
invasiveness through a phenomenon called phenotypic switch system or white-opaque transition, 
described in 1987. 
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Figure 2. The estimated number of people with diabetes worldwide and per region in 2045 between 
20–79 years in age, with a total of 629 million (source: International Diabetes Federation) (adapted 
image from GraphicsRF on stock.adobe.com). 
This involves reversible and heritable switching between alternative cellular phenotypes. It 
occurs at sites of infection and recurrently in episodes of infection in certain cases in diabetic 
patients[33]. 
Yeasts are part of the normal gut microflora, but cell counts do not normally surpass 10 colony 
forming units (CFU)/g feces [34,35]. Nevertheless, it has been described that Candida sp. is more 
widespread in the feces of patients with type 1 and type 2 DM with poor glycemic control as opposed 
to healthy subjects [36]. The main reasons for this colonization seem to be altered functions of the 
immune system in diabetic patients with poor glycemic control or a direct effect of elevated blood 
glucose levels, creating specific conditions for intensive fungal colonization [36]. In fact, another 
report [37] showed that in patients with type 1 DM, the total gut CFUs significantly rise up to 40% in 
C. albicans colonization compared to 14.3% in healthy individuals. This may be related to the decrease 
in commensal bacteria-probably the result of yeast-bacterial competition. Also, this higher growth 
may disrupt the ecological balance of intestinal flora, which occurs in type 1 DM [37]. Regarding the 
gastrointestinal colonization, Kowalewska et al. [38] studied the serum levels of interleukin-12 (IL12) 
in relation to the percentage of yeast-like fungi colonies residing in the gastrointestinal tract in 
children and adolescents with DM type 1. Results showed that high IL12 levels can inhibit infection 
with yeast-like fungal colonizing the gastrointestinal tract in children and adolescents with type 1 
DM. However, further studies are needed to confirm the antifungal activity of IL12 [38]. 
The development of drug resistance among Candida sp. isolates allied to epidemiologic 
variations in Candida sp. natural flora has significant implications for morbidity and mortality[39–
42]. The extensive use of medications, especially azoles, has promoted the selection of resistant 
species by shifting colonization to more naturally resistant Candida sp., such as C. glabrata, C. 
dubliniensis, and C. krusei [43–46]. Presently, the world distribution of Candida sp. is a feature of the 
epidemiology in the area, but it indicates a predominance of C. albicans, C. glabrata, C. tropicalis, C. 
parapsilosis, and C. krusei [45,47]. It has been confirmed that 90% of fungemia cases are attributed to 
J. Clin. Med. 2019, 8, 76 4 of 40 
 
Candida sp. [39,40], and the mortality has ranged from 40% to 80% in immunocompromised hosts 
[39,40,48]. Furthermore, a high mortality rate was also detected among non-immunocompromised 
patients (60%) [49] and those with diabetes (67%)[41]. 
The main pathophysiologic and nutritionally relevant sugars in diabetic patients are glucose and 
fructose, but other simple carbon sources also play an important part in the growth of Candida sp. in 
DM patients. Man et al. [50] evaluated the growth rate of C. albicans in the presence of different 
concentrations of glucose and fructose to obtain a better understanding of the nutrient acquisition 
strategy and its possible relation to the hyperglycemic status of diabetic patients. The authors 
determined that the glucose concentration is directly related to C. albicans growth, which may be 
linked to the frequent yeast infections that occur in non-controlled diabetic patients. Interestingly, 
fructose showed C. albicans inhibition capacities. This implies fructose-containing food may prevent 
the development of candidiasis. This is an important outcome in oral Candida sp. biofilms, especially 
for patients who use prosthesis [50]. In fact, other carbon compounds such as sucrose, maltose, and 
lactose increase the fungal population density [43,51,52] and decrease the activity of antifungal 
agents. A recent report explored the effects of glucose in diabetic mice on the susceptibility of Candida 
sp. to antifungal agents [53]. In that work, Mandal et al. [53] revealed that voriconazole (Vcz) has the 
greatest reduction in antifungal drug efficacy followed by amphotericin B (AmB). Glucose displayed 
a higher affinity to bind to Vcz through hydrogen bonding, decreasing the susceptibility of antifungal 
agents during chemotherapy. Additionally, Mandal et al. [53] confirmed that Vcz presented three 
important hydrogen bonds and AmB presented two hydrogen bonds that stabilized the glucose. In 
vivo results of the same study proposed that the physiologically relevant higher glucose level in the 
bloodstream of mice with DM might interact with the available selective agents during antifungal 
therapy, decreasing glucose activity by complex formation. Vcz-glucose and AmB-glucose complexes 
seem to present less effectiveness as their pure molecule. Accordingly, a proper selection of drugs for 
DM patients is important if we are to control infectious diseases [53]. Similarly, Rodaki et al.[54] 
studied the impact of glucose on C. albicans transcriptome for the modulation of carbon assimilatory 
pathways during pathogenesis. The elevated resistance to oxidative and cationic stresses and 
resistance to miconazole uncovered that glucose concentrations in the bloodstream have a significant 
impact upon C. albicans gene regulation. No significant susceptibility level was perceived for 
anidulafungin, while Vcz and AmB became less effective [54]. In another study, Rodrigues et al. [52] 
demonstrated that C. glabrata decreases its susceptibility to fluconazole when cultured in a medium 
enriched with glucose [52]. 
Accordingly, the aim of this review is to analyze the literature related to the occurrence of 
candidiasis in diabetic patients by discussing specific features of Candida sp. that relate directly to the 
occurrence of candidiasis in DM patients and related diseases, as well as by reviewing recent and 
relevant studies on the topic. 
2. Particular Features of Candida sp. that Increase the Incidence of Candidiasis in Diabetic 
Patients 
2.1. Enzymatic Activity 
Several studies have established an association between hydrolytic enzymes activity and an 
increase in the pathogenic ability of Candida sp. [55,56]. 
It has been demonstrated that, due to higher blood glucose concentration, diabetic Candida sp. 
isolates present significantly higher hemolytic and esterase enzymatic activity, which may contribute 
to increased enzyme activity among diabetic patients [57–60]. The same authors also hypothesized 
that these species are more pathogenic under abnormal conditions such as DM [61,62]. Secreted 
aspartyl proteinases (SAP) capable of degrading numerous substrates that constitute host proteins in 
the oral cavity have also been studied. These enzymes are thought to help Candida sp. to acquire 
essential nitrogen for growth, to attach to and penetrate oral mucosa, or both [63,64]. They can also 
cause amplified vascular permeability, leading to inflammatory reactions [65] and clinical symptoms, 
which may disturb the humoral host defense [66]. Similarly, phospholipase (PL) targets the 
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membrane phospholipids and digests these components, initiating cell lysis and facilitating the 
penetration of the infecting fungi [67]. This enzyme induces the accumulation of inflammatory cells 
and plasma proteins, releasing several inflammatory mediators in vivo [67]. 
Very recently, it was revealed that C. albicans hyphae induce both epithelial damage and innate 
immunity through the secretion of a cytolytic peptide toxin called candidalysin [68,69]. This enzyme 
is encoded by the hypha-associated ECE1 gene and is the first peptide toxin to be identified in any 
human fungal pathogen. Candidalysin induces calcium ion influx and lactate dehydrogenase (LDH) 
release in oral epithelial cells, which are features of cell damage and membrane destabilization. 
Importantly, the study also reported that C. albicans mutants where the entire ECE1 gene or the 
candidalysin-encoding region had been deleted have full invasive potential in vitro but are incapable 
of inducing tissue damage or cytokine release and are highly weakened in a mouse model of 
oropharyngeal candidiasis and a zebrafish swim bladder mucosal model [68]. 
2.2. Biofilm Formation 
Biofilms are communities of microorganisms embedded in an extracellular matrix [70,71], which 
confer substantial resistance to antifungal therapy and increased host immune responses [72,73]. 
These communities can be formed in both biotic (e.g., mouth mucosae) or abiotic (e.g., catheters) 
surfaces [74,75]. In fact, candidemia are the most prevalent invasive mycoses worldwide with 
mortality rates close to 40% [76]. Candida sp. are often recognized as the origin of candidemia, urinary 
tract infections, and hospital pneumonia. In practically all of these cases, the infections are related 
with the use of a medical device and biofilm formation on its surface [20]. The most frequently 
colonized medical device is the central venous catheter used for administration of fluids, nutrients, 
and medicines [77]. The contamination of the catheter or the infusion fluid can arise from the skin of 
the patient, the hands of health professionals [77], or by migration into the catheter from a pre-
existing lesion. Less commonly, if Candida sp. that colonize the gastrointestinal tract as a commensal 
start to develop a pathogenic behavior, they are able to infiltrate the intestinal mucosa and diffuse 
through the bloodstream. Consequently, circulating yeast may colonize the catheter endogenously. 
This is more common in cancer patients, as chemotherapy leads to damage to the intestinal mucosa 
[78]. In the other patients, infected catheters are the most significant source of bloodstream infections, 
followed by widespread invasive candidiasis. The catheter removal is recommended in patients with 
disseminated Candida sp. infection to enable disinfection of the blood and to increase prognosis 
[79,80]. 
Biofilm development of Candida sp. (Figure 3) can be explained in four chronological steps: 
adherence-initial phase in which the yeast in suspension and planktonic cells adhere to the surface 
(first 1–3 h); intermediate phase-development of biofilm (11–14 h); maturation phase-the polymeric matrix 
(PEM) completely penetrates all layers of the cells adhered to the surface in a three-dimensional structure 
(20–48 h); dispersion-the most superficial cells leave the biofilm and colonize areas surrounding the 
surface (after 24 h) [81]. Hence, a mature biofilm comprises of a dense network of cells in the form of 
yeasts, hyphae, or pseudohyphae (or not, depending on the Candida sp.) involved by PEM and with 
water channels between the cells. These help in the diffusion of nutrients from the environment 
through the biomass to the lower layers and also allow the removal of waste [81,82]. Formed using 
in vivo models, Candida sp. biofilms seem to follow the same sequence of in vitro formation [83]. 
Nonetheless, the maturation step happens more quickly, and the thickness is increased. The final 
architecture of the biofilm is variable and depends, in part, on the Candida sp. involved, the growing 
conditions, and the substrate on which it is formed [81,84]. 
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Figure 3. Development of a Candida sp. biofilm in a surface. 
High levels of glucose are thought to serve as the carbohydrate energy source necessitated by 
Candida sp. for the biofilm formation and are probably required to produce the polysaccharide matrix 
[85], which is secreted by sessile cells, providing protection against environmental challenges [86]. 
Biofilm formation has been shown to be dependent on the Candida sp. and its clinical origin. Biofilms 
are refractory to antifungal drugs and more difficult to treat than infections with planktonic cells [44]. 
Moreover, it has been verified that Candida sp. isolated from patients with DM have a higher 
pathogenic potential for biofilm-forming [87]. The communities are extremely common on medical 
devices. 
2.3. Hydrophobicity 
In Candida sp., the adhesion phenomenon is mediated by agglutinin-like (Als) sequence proteins [88], 
which are glycosylphosphatidylinositol (GPI)-linked to β-1-6 glucans in the fungal cell wall. Als-
dependent cellular adhesion is connected with increases in cell surface hydrophobicity (CSH) [89]. 
The CSH of Candida sp. enhances virulence by promoting adhesion to host tissues [89,90]. C. albicans 
Als3p (hypha-associated) is a major epithelial adhesin that is strongly upregulated during epithelial 
infection in vitro [90], and the disruption of the ALS3 gene reduces epithelial adhesion in vitro. 
Likewise, decreasing the expression of the ALS2 gene also reduces adhesion [91,92]. On the other 
side, deletion of the ALS5, ALS6, or ALS7 genes increased adhesion [93], demonstrating that the Als 
proteins can have opposing roles in fungal attachment to surfaces. Putative homologues of Als 
proteins have also been identified in NCAC[94]. In C. glabrata, for example, epithelial adhesins (Epa) 
have a comparable structure to the Als proteins [95,96]. 
Together with adhesion ability, hydrophobicity is a virulent factor that is gene-regulated and 
usually positively correlated with biofilm metabolic activity [97,98] since hydrophobic interactions 
seem to be crucial in promoting tissue invasion by the mycelial phase of Candida sp. It is presumed 
that Candida sp. can grow under anaerobic conditions, although in these conditions fermentation is 
the dominant pathway for ATP production [99]. The results of Sardi et al. [100] indicated that 51.97% 
of diabetic patients’ isolates were highly hydrophobic under anaerobic conditions when compared 
to 21.90% under the aerobic atmosphere [100]. It is recognized that the germ tubes are able to adhere 
to fibronectin, fibrinogen, and complement via cell surface receptors [101], helping the attachment of 
filament yeasts to extracellular matrix components (ECM)[102] and producing impairment of 
phagocytosis, consequently increasing the resistance to blood clearance and the virulence of Candida 
sp. [103]. 
3. Candidiasis and DM 
3.1. Oral Diseases 
3.1.1. Oral Candidiasis 
The prevalence of oral candidiasis is increasing, as it is one of the most common fungal infections 
[104]. Oral candidiasis can be diagnosed by the differential patterns of mucosal changes like 
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erythematous, pseudomembranous, and curd-like plaques (biofilms)[105,106]. Higher Candida sp. 
colonization rates were reported in patients with DM type 1 when compared to DM type 2 patients 
(84% vs. 68%, respectively), while the percentage in nondiabetic subjects was around 27% [18]. The 
studies also describe how this colonization does not always lead to infection. Nonetheless, it is a 
prelude to infection when host immunity is compromised and the risk of a disseminated infection is 
high [107]. Such infections continue to be a major healthcare challenge [108]. 
The risk factors for oral candidal infection are complex, but it is known that tongue lesions, 
tobacco smoking, denture wearing, and immunosuppression (e.g., diabetes mellitus) clearly 
influence oral Candida sp. carriage and the upsurge of oral candidiasis [30,109–114]. The causes 
influencing the higher incidence of oral candidiasis in diabetic patients are presented in Table 1. 
Higher expressions in enzymatic activity and the biofilm forming capacity of Candida sp. are two 
of the most important features in oral candidiasis. In a study by Sanitá et al. [115], the virulence of 
148 clinical isolates of C. albicans from oral candidiasis was characterized by measuring the expression 
of PL and SAP in healthy subjects (HS), diabetics with oral candidiasis (DOC), and non-diabetics with 
oral candidiasis (NDOC). For PL, C. albicans from NDOC and DOC had the highest enzymatic activity 
(76.6%); for SAP, C. albicans from NDOC exhibited lower enzymatic activity (48.9%). Similar results 
have been reported in the past [59,87], with percentages greater than 90% for both PL and SAP activity 
among clinical isolates of C. albicans [26,116,117] found. Arlsan and colleagues found 12 different 
genotypes and compared the virulence factors of several Candida sp. isolated from the oral cavities of 
142 healthy and diabetic individuals, with and without caries. Although the most isolated species 
was also C. albicans, there were statistical differences in terms of isolated Candida frequency between 
healthy subjects and diabetic patients. DM showed no effect on the activities of virulence factors 
(biofilm production, proteinase, and phospholipase activity) of Candida sp. Yet, different genotypes 
of C. albicans exhibited different virulence activities[118]. Other authors showed that the activity of 
SAPs suggestively rises in denture wearers with signs of candidiasis compared to denture wearers 
with a normal palatal mucosa [119]. The inconsistency of results of these reports can be explained by 
the large variation of intra-and interspecies of Candida and deviations in the methodology in most 
reports [24,26,123,59,87,116,117,119–122]. A longitudinal study by Sanchés-Vargas et al. [124] 
quantified biofilms in oral clinical isolates of Candida sp. from adults with local and systemic 
predisposing factors for candidiasis. Between the isolates, authors found C. albicans, C. tropicalis, C. 
glabrata, C. krusei, C. lusitaniae, C. kefyr, C. guilliermondii, and C. pulcherrima from the oral mucosa of 
totally and partially edentulous patients (62.3%) and the oral mucosa of diabetics (37.7%). On 
average, the oral isolates of C. glabrata were considered strong biofilm producers, whereas C. albicans 
(the most common species) and C. tropicalis were moderate producers. This might be because C. 
glabrata has been shown to have a higher aggressiveness, producing a great quantity of biofilm 
matrices yet also increasing chitin concentrations in the cell walls [125–127]. 
Additional important features are the oral pH and the glycemic control. A study performed by 
Samaranayake et al. [128] demonstrated that pyruvates and acetates are the major ionic species, 
generating a quick decrease in pH with Candida sp., as found in batch cultures of mixed saliva 
supplemented with glucose [128]. 
Other authors indicated that yeasts have a superior ability to adhere to epithelia and denture 
acrylic surfaces at a low pH of approximately 2–4.14 [31,129]. Balan and colleagues stated that during 
hyperglycemic episodes, the environmental alteration in the oral cavity increased salivary glucose 
and acid production, which favored the transition of Candida sp. from commensal to pathogen [31]. 
In another report, while comparing diabetics and non-diabetics, Pallavan et al. [130] verified that 70% 
of the healthy individuals had lower colonization and 43.3% of the diabetic patients had severe 
colonization by Candida sp., which was also observed in other studies [14,18,21,131]. Prediabetes is a 
condition where there is an elevation of plasma glucose above the normal range but below that of 
clinical diabetes [132]. Javed and their colleagues isolated oral Candida sp. from 100% of patients with 
prediabetes and from 65.7% of the controls, observing that the carriage of C. albicans was greater 
among patients with prediabetes (48.7%) than with controls (25.7%)[133]. They also observed that the 
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colonization with Candida sp. reduced the salivary flow rate and was independent of glycemic status 
in patients with prediabetes [132]. 
In fact, while some studies found a direct significant association between glycosylated 
hemoglobin and oral Candida colonization[134,135], other authors found no relationship between 
glycosylated hemoglobin and high Candida-burden in patients with DM [14,18,136,137]. Furthermore, 
studies indicate that the concentration of glucose present in the gingival crevicular fluid is related to 
the blood glucose level [138]. The quality of glycemic control can also partially explain the presence 
of a significant relationship between subgingival plaque candidal colonization and higher 
concentrations of glucose [138]. 
Although most of the scientific community believes that diabetes is a risk factor associated with 
oral yeast infections, in a recent paper, Costa and colleagues [139] reported that the presence of yeasts 
in the oral cavity of patients with type 1 DM (60% of total) was not affected by diabetes, metabolic 
control, duration of the disease, salivary flow rate, or saliva buffer capacity by age, sex, place of 
residence, number of daily meals, consumption of sweets, or frequency of tooth brushing. Candida 
albicans was the most prevalent yeast species, but a higher number of yeast species was isolated in 
nondiabetics [139]. The fact that this study was developed exclusively in children may be related to 
this conclusion. 
Table 1. Physiopathology and etiology related to the occurrence of oral candidiasis in diabetics. 
 Physiopathology Reference(s) 
Uncontrolled 
hyperglycemia  
(high HbA1c) 
and  
high glucose 
levels in saliva 
-Uncontrolled hyperglycemia may cause intensification 
in salivary glucose levels because in diabetics the 
basement membrane of the parotid salivary gland is 
more permeable 
-High glucose levels allow Candida sp. to multiply, even 
in the presence of normal bacterial flora 
-During hyperglycemic episodes, the chemically 
reversible glycosylation products with proteins in tissues 
and the accumulation of glycosylation products on 
buccal epithelial cells may sequentially increase the 
number of available receptors for Candida sp. 
-Glucose suppression of the killing capacity of 
neutrophils, emphasizing colonization 
(immunosuppression)  
-Glucose, maltose, and sucrose boost the adhesion of 
Candida to buccal epithelial cells  
[15,29,145–
147,31,52,134,140–
144] 
Lower salivary 
pH 
-The growth of Candida in saliva is accompanied by a 
rapid decline in pH, which favors their growth and 
triggers the extracellular phospholipase (PL) and acid 
proteases, increasing the yeast adhesion to oral mucosal 
surfaces 
[31,128,148] 
Tissue response 
to injury is 
diminished  
-Diabetes mellitus (DM) is known to diminish the host 
resistance and modify the tissue response to injury. This 
can result in severe colonization, even in the absence of 
any clinically evident oral candidiasis and possibly with 
further dissemination via the blood. 
[130,149] 
Oral epithelium 
-It is most probable that the host oral epithelium of 
patients with diabetes favors the adhesion of colonization 
and subsequent infection. 
[150,151] 
Poor oral 
hygiene 
The lack of control of the oral environment, especially 
concerning the prevention of dental caries (coronary, 
[152–154] 
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root, and periodontal), leads to a higher rate of oral 
candidiasis, especially in DM older patients 
Aging Diabetic women, orally colonized with Candida sp. have 
higher oral glucose levels than diabetics without oral 
Candida sp. 
[134] 
Gender 
Prostheses 
Inadequate use of prostheses, together with inadequate 
hygienization, favours the growth of Candida sp. 
[155–157] 
Drugs 
Xerostomia (abnomal lack if saliva): Candida sp. 
stagnation and growth on oral tissues  
[30,109–
111,136,158,159] 
3.1.2. Antifungal Treatment of Oral Candidiasis 
Importantly, several reports have stated the importance of the evaluation of the susceptibility of 
the oral isolates to the antifungal drugs in order to choose proper therapy in diabetic patients to 
control the fungal diseases. Aitken-Saavedra et al. [160] revealed that 66% of the yeasts isolated in 
diabetic patients were C. albicans, followed by C. glabrata (20.7%). In patients with decompensated 
type 2 DM, higher levels of salivary acidification and a greater diversity and quantity of yeasts of the 
genus Candida were observed. When nystatin was administered in these patients, higher inhibition 
was observed at a lower pH[160]. The study presented by Lydia Rajakumari and Saravana Kumari 
[161] showed a lower glycemic control leads to a higher candidal colonization in diabetic patients. 
The predominant species was C. albicans, but among denture wearers, C. glabrata was predominant. 
More importantly, ketoconazole, fluconazole, and itraconazole were effective against the isolated 
Candida sp.[161]. 
Similarly, Premkumar et al. [162] stated that, although C. albicans was the most predominantly 
isolated species, C. dubliniensis, C. tropicalis, and C. parapsilosis were also observed. The authors 
showed variable resistance toward amphotericin B, and fluconazole was observed in clinical isolates 
from diabetics but not from healthy patients. Again, a positive correlation was observed between 
glycemic control and candidal colonization [162]. In 2011, Bremenkamp et al. [163] found no 
significant differences in antifungal susceptibility to the tested agents between Candida sp. isolates 
from diabetic and non-diabetic subjects, which was consistent with the study by Manfredi et al. [164]. 
Furthermore, a high prevalence of C. dubliniensis in diabetic patients was found, which may suggest 
a potential misdiagnosis of its morphologically-related species, C. albicans. Other authors found the 
same two species in DM patients [1,16,57,135]. In yet another study, Sanitá and their colleagues [165] 
investigated the susceptibility of 198 oral clinical isolates of Candida sp. against caspofungin, 
amphotericin B, itraconazole, and fluconazole. Their findings confirmed the resistant profile of C. 
glabrata isolates against azole antifungals—especially itraconazole—in individuals with diabetes and 
denture stomatitis. The clinical sources of the isolates were shown to have no effect on the mininum 
inhibitory concentration (MIC) values obtained for all antifungals tested, which was in accordance 
with previous reports [26,119]. Additionally, Candida sp. isolates with higher rates of resistance to 
flucytosine, ketoconazole, miconazole, and econazole were confirmed in patients with diabetes when 
compared to healthy controls [163,166]. The increase in the environment glucose concentration may 
trigger the expression of several genes responsible for several carbohydrate cell wall and biofilm 
matrices components, consequently leading to resistant strains. This has been demonstrated before 
in gene and drug studies [126]. The variability in the susceptibility results may be related to the 
different antifungal drugs tested in those works. 
Using a different approach, Mantri et al. [149] evaluated Candida sp. colonization in dentures 
with a silicone soft liner in diabetic and non-diabetic patients, assessing the antifungal efficacy of 
chlorhexidine gluconate [149]. The results showed normal oral flora in diabetics and non-diabetics 
and no difference between groups. They also showed a significant reduction of the colonization after 
cleaning the dentures with 4% chlorhexidine gluconate. This suggests that this drug has a good 
antiseptic effect on Candida sp. by killing it and preventing new adhesion. In 2015, Indira et al. [167] 
conducted a study that compared the common opportunistic infections (OIs) between 37 people 
living with HIV with DM (PLHIV-DM) and 37 people living with HIV without DM (PLHIV). Both of 
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the groups were treated with anti-retroviral therapy (ART)[167]. The most common Ois included oral 
candidiasis (49% of PLHIV-DM and 35% of PLHIV) and C. krusei was the most common Candida sp. 
isolated (50%). No significant difference in the profile of Ois was found between PLHIV with and 
without DM. 
3.1.3. Periodontal Diseases 
Periodontal diseases of fungal origin are relatively unusual in healthy individuals but arise more 
often in immunocompromised people or in cases when normal oral flora has been distressed (e.g., 
the use of broad-spectrum antibiotics)[168,169]. Diabetes is a stated risk factor for periodontitis, 
which is the sixth-leading complication of diabetes [170,171]. Alterations in host response, collagen 
metabolism, vascularity, gingival crevicular fluid, heredity patterns, and immunosuppressive 
treatment (drugs, dosage, and treatment duration) are known factors that promote periodontitis in 
diabetes [172,173]. The etiology and pathogenesis of periodontitis is still imprecise, but it is 
recognized that Candida sp. is part of the oral and subgingival microbiota of individuals who suffer 
from severe periodontal inflammation [174]. The virulence factors of Candida sp. simplify the 
colonization and the proliferation in the periodontal pockets by co-aggregating with bacteria in 
dental biofilms and adhering to epithelial cells [30], which are essential in the microbial colonization, 
thereby contributing to the evolution of oral diseases [175,176]. As much as 20% of patients with 
chronic periodontitis have been shown to have periodontal pockets that are colonized by several 
species of Candida sp., predominantly C. albicans [177,178], but C. dubliniensis [174], C. glabrata, and C. 
tropicalis have been reported too [176,179]. Furthermore, C. albicans strains isolated from subgingival 
sites of diabetic and periodontal patients showed high PL in cases of chronic periodontitis. 
Environmental oxygen concentration demonstrated influence on the virulence factors [100,180,181]. 
Sardi et al. [100], in a study using PCR experiments, demonstrated that the quantities of several 
Candida sp. were higher in diabetic patients with a chronic periodontal disease than in patients 
without diabetes. C. albicans, C. dubliniensis, C. tropicalis, and C. glabrata were detected in 57%, 75%, 
16%, and 5% of the periodontal pockets, respectively. In non-diabetic patients, C. albicans and C. 
dubliniensis were present in 20% and 14%, respectively. Periodontal inflammation has been described 
to be worse in prediabetics when compared to healthy controls [182–185], assuming that the oxidative 
stress induced by chronic hyperglycemia with a reduced unstimulated whole salivary flow rate 
(UWSFR) in these patients may contribute to deteriorating periodontal status [133]. Thus, it has been 
suggested that glycemic control enhances healing and reduces periodontal inflammation in patients 
with DM and prediabetes [134,182,185–191]. As a result, some authors believe that it may reduce oral 
Candida sp. carriage in patients with prediabetes [133]. The HbA1c concentration is an important 
diagnostic tool for monitoring long-term glycemic control [192]. Also, in these cases, higher Candida 
sp. infection levels have also been associated with low diabetic control (HbA1c >9), occurring less 
frequently in subjects with well-controlled blood sugar levels (HbA1c <6). 
3.1.4. Denture Prosthetics and Candidiasis 
Since the oral cavity is highly populated with several polymicrobial communities, each one 
occupies very precise niches that diverge in both anatomical location and as well as nutrient 
availability [193]. A consequence of strong commensal bacteria/yeast colonization is the inhibition of 
pathogenic microorganism colonization through resistance. The vital function of commensal yeast 
and bacteria and the harmful effects of commensal depletion through the use of broad spectrum 
antibiotics [194,195] are well recognized. Recent studies disclosed that commensal microorganisms 
not only protect the host by niche occupation, but also interact with host tissue, promoting the 
development of proper tissue structure and function [196,197]. 
Dentures represent a protective reservoir for oral microorganisms, mostly in biofilm form, 
favoring yeast proliferation, improving their infective potential, and protecting fungal cells against 
several medications [198–202]. Elderly edentulous denture wearers, patients with debilitating 
diseases, and users of acrylic prosthetics have a significant risk of virulent oral yeast infections [124]. 
Furthermore, elderly patients with diabetes have a 4.4 times higher estimated risk of developing oral 
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candidiasis when compared with individuals without this disease. No statistically significant relation 
was determined between xerostomia, the use of prosthesis, and oral candidiasis[154], as suggested 
by some studies [203,204]. Sanitá et al. [199] studied the prevalence of Candida sp. in diabetics and 
non-diabetics with and without denture stomatitis (DS) and found that C. albicans was the 
predominant species isolated in the three groups (81.9%). They also detected C. tropicalis (15.71%) 
and C. glabrata (15.24%), as found in previous studies [10,14,206–210,15,21,24,57,136,144,173,205]. 
Interestingly, and contrary to other reports, the authors did not detect C. dubliniensis among any 
Candida sp. isolates. Even though these results confirm previous findings 
[10,14,209,210,16,21,24,26,136,144,173,207], this species has been isolated in both diabetic[12,57,206] 
and non-diabetic [208] patients. This discrepancy among studies may be related to problems with 
identification techniques, since C. dubliniensis and C. albicans have similar phenotypic characteristics. 
The same authors also found that the prevalence of C. tropicalis significantly increased, showing the 
highest degree of inflammation in DS, as observed in previous studies [12,16,24,136,144,173,208–210]. 
3.1.5. Co-Occurrence of Dental Plaque, Periodontitis, and Gingivitis 
The existence of numerous different oral diseases in a single patient is frequent in diabetics. 
Hammad et al. [29] studied the relationship between the tongue and subgingival plaque Candida sp. 
colonization, as well as its relationship with the quality of glycemic control in type 2 diabetics with 
periodontitis. The results showed that Candida sp. colonized 59% and 48.7% of the patients’ tongues 
and subgingival plaque, respectively. In this cross-sectional study, the authors concluded that poorly 
controlled type 2 diabetics and female patients with periodontitis showed a higher prevalence of 
subgingival plaque Candida sp. colonization than men, regardless of oral hygiene, tobacco smoking, 
age, or duration of DM [29]. The authors could not correlate oral candidal colonization and the 
amount of dental plaque, a patient’s gingival status, or oral hygiene, as in other studies [211], but 
noticed Candida sp. present in the dental plaque in the form of biofilm. Remarkably, and compared 
with the control group, they found that C. albicans cells isolated from the subgingival plaque of 
patients with periodontitis adhered more to epithelial cells [212], suggesting that the oxygen 
concentration in the periodontal pockets affects the virulence of C. albicans [213]. A study that 
evaluated the effect of Candida sp. and general disease- or treatment-related factors on plaque-related 
gingivitis severity in children and adolescents with Nephrotic syndrome (NS, a clinical condition 
with a proteinuria level exceeding the body’s compensating abilities) and diabetes concluded that 
poor hygiene control was the main cause of gingivitis. Olczak-Kowalczyk and colleagues [172] 
showed in their work that Candida sp. often occurred in healthy patients, but oral candidiasis was 
found only in the NS and diabetes groups (9.37% and 11.43%). Their work also showed that gingivitis 
occurred more frequently in patients with NS/diabetes. Moreover, gingivitis severity was most likely 
correlated to age, lipid disorders, and an increase in body mass and Candida sp. In uncompensated 
diabetes and in those patients using immunosuppressive treatment, it was assumed that NS would 
increase the plaque-related gingivitis. 
3.1.6. Esophagitis and Oropharyngeal Candidiasis 
Candida sp. esophagitis and oropharyngeal are also oral complications found to moderately 
affect DM patients. Recently, Takahashi et al. [214] determined long-term trends in Candida sp. 
esophagitis (CE) prevalence and associated risk factors for patients with or without HIV infections. 
A risk analysis revealed that, among other factors, DM is associated with CE. Also, Mojazi and their 
colleagues [215] identified risk factors for oropharyngeal Candida sp. colonization in critically ill 
patients, with the results confirming DM as a risk factor [215]. Likewise, Owotade and colleagues 
[216] investigated the role of anti-retroviral (ARV) therapy and other factors related to oral 
candidiasis. Results demonstrated that 59.4% of the individuals were colonized by yeasts. C. albicans 
was the most common species (71%) and C. dubliniensis was the most frequent non-Candida albicans 
Candida species (NCAC). The probabilities of colonization were five times greater in patients with 
diabetes [216], confirming previous findings [16]. 
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Oral and esophageal candidiasis sometimes leads to mucosal hyperplasia and progresses to 
carcinoma. There are many reports of the antibacterial effects of probiotics, but consensus about their 
antifungal effect has not been reached. In order to find alternative therapies, Terayama et al. [217] 
investigated whether probiotic (yogurt) containing Lactobacillus gasseri OLL2716 (LG21 yogurt) could 
prevent proliferative and inflammatory changes caused by C. albicans in a mucosal candidiasis animal 
model. Diabetes was induced in eight-week-old WBN/Kob rats by the intravenous administration of 
alloxan. The results suggested that probiotic (yogurt) containing L. gasseri OLL2716 can suppress 
squamous hyperplastic change and inflammation associated with C. albicans infection in the 
forestomach [217]. 
3.2. Vulvovaginal Candidiasis 
The exact association between DM and vulvovaginal candidiasis (VVC) remains to be clarified, 
but some investigations propose that the general reduced immune response associated with DM is 
the main cause of recurrent VVC [218–221]. Additionally, diabetes type, severity, and degree of 
glucose control are probable risk factors associated with VVC prevalence, and it is acknowledged 
that the metabolic disorders that predispose to clinical vaginitis can be reduced by performing an 
appropriate diabetic control [222,223]. C. albicans is the most common species isolated, followed by 
C. glabrata in patients both with and without diabetes [219,224,225]. Studies have been reporting an 
increased frequency of infection by NCAC over time [226,227], especially C. glabrata, which is more 
recurrently associated with VVC in African and Asian countries [228–231]. Table 2 summarizes the 
metabolic disorders that can predispose one to VVC and those that can be decreased with proper 
diabetic control. 
Several studies explored the association between VVC and DM. Gunther et al. [232] investigated 
the frequency of total isolation of vaginal Candida sp. and its different clinical profiles in women with 
type 2 DM compared to non-diabetic women in Brazil [232]. Vaginal yeast isolation occurred in 18.8% 
in the diabetic group and in 11.8% of women in the control group. The diabetic group was shown to 
be more symptomatic (VVC + recurrent VVC (RVVC) = 66.66%) than colonized women (33.33%), and 
indicated more colonization, VVC, and RVVC than the controls. Sherry et al. [233] studied the 
epidemiology of VVC in a cohort in order to find the causative organisms associated with VVC. The 
authors noticed a shifting prevalence of Candida sp. with C. albicans as the most common yeast but an 
increase of NCAC. A heterogeneous biofilm-forming capacity associated with lower antifungal drug 
sensitivity was also reported. 
On the contrary, Ray et al. [234] stated that out of 11 diabetic patients, C. glabrata was isolated in 
61.3% and C. albicans in 28.8% of VVC cases [234]. Other studies have shown similar results in diabetic 
women [221,235,236]. Results showed a persistent vaginal colonization with C. glabrata in 
estrogenized streptozotocin-induced type 1 diabetic mice, and vaginal polymorphonuclear (PMN) 
infiltration (constantly low) was found in a murine model study by Nash and colleagues [237]. 
Contrary to what happens in women and in other in vivo studies, in this case, curiously, biofilm 
formation was not detected, and co-infection of C. glabrata with C. albicans did not induce synergistic 
immunopathogenic effects [237]. 
Table 2. Physiopathology and etiology related to the occurrence of vulvovaginitis in diabetics. 
Condition Physiopathology Reference(s) 
Uncontrolled 
hyperglycemia 
(high HbA1c) 
and  
high glucose levels 
in vaginal 
mucosae 
- The increased serum glucose level is thought to 
lead to impaired monocyte, granulocyte, and 
neutrophil adherence, as well as reduced 
chemotaxis, phagocytosis, and pathogen killing 
- Diabetics secretions contain glucose, which can be 
used as a nutrient by yeasts 
- pH, nutritional substance, temperature, and 
adherence capacity in the vulvovaginal tissue may 
induce Candida sp. virulence. The vaginal epithelial 
[55,56,240–
249,59,250–
253,219,222,224,225,2
31,238,239] 
J. Clin. Med. 2019, 8, 76 13 of 40 
 
cell receptor of fucose supports the adhesion of 
Candida sp. to vaginal epithelial cells 
-The rise in vaginal glucose and secretions and 
activities of hydrolytic enzymes [e.g., secreted 
aspartyl proteinases (SAPs), PL] increases the 
pathogenicity of Candida sp. 
-Increased levels of glycogen increase colonization 
and infection by Candida sp. by lowering the vaginal 
pH, facilitating the development of vulvovaginal 
candidiasis (VVC) 
Pregnancy 
-The increased circulation of estrogen levels and the 
deposition of glycogen and other substrates in the 
vagina leads to a 10–50% higher incidence of 
vaginal colonization by Candida sp.  
-Variability of constitutive defensins (e.g., 
lactoferrins, peptides) and lysozyme, leading to a 
poor innate immune response 
-Hyperglycemia can rise the anaerobic glycolysis in 
vaginal epithelial cells, increasing lactic acid and 
acetone production, decreasing the vaginal pH, thus 
enabling fungal colonization and proliferation 
[241,254–260] 
Diabetes type  
- The incidence of VVC related to the type 1 DM or 
type 2 DM and is variable among studies 
[218,221–223] 
Aging - The older one is, the higher VVC prevalence is [222,223] 
In a different study, Nyirjesy and colleagues evaluated the effects of sodium glucose co-
transporter 2 inhibitors (e.g., canagliflozin, dapagliflozin, sitagliptin) used for the treatment of type 2 
DM. These drugs improve glycemic control by increasing urinary glucose excretion and are related 
to increased vaginal colonization with Candida sp. and in VVC adverse events in women with type 2 
DM[252]. Of the nine subjects with VVC with a positive vaginal culture at the time of the adverse 
event, six cultures were positive for C. albicans, only one was positive for C. glabrata, and one was 
positive for C. tropicalis. These findings confirm previous suggestions that C. glabrata is less 
pathogenic than C. albicans and more often associated with asymptomatic colonization in VVC [261]. 
The investigation theorized that urinary glucose excretion and the subsequent deposition of urine on 
the vulvovaginal tissues with voiding are more significant factors in increasing the risk of VVC in 
diabetic women than overall glycemic control. In this study, women showed improved glycemic 
control due to the administration of canagliflozin [262,263] with a higher prevalence of Candida sp. 
colonization and symptomatic infection, which was also detected with dapaglifozin[264]. Also 
related to SGLT2 inhibitors, the prevalence and risk of VVC before SGLT2 inhibitors was carefully 
evaluated in real-world practice by Yokoyama and colleagues [265]. They reported that before 
starting SGLT2 inhibitors, 14.9% of the participants had positive vaginal Candida sp. colonization. 
Younger age and the presence of microangiopathy were significantly associated with the 
colonization. Moreover, of the 65 participants who were negative for Candida sp., 24 participants 
(36.9%) converted to a positive culture, and 18 participants (15.8%) developed symptomatic vaginitis. 
The authors concluded that the rates of developing positive colonization and symptomatic vaginitis 
after starting SGLT2 inhibitors appear to be higher in real-world practice than the rates of 31% and 
5–10% in clinical trials, respectively. Risk factors of vaginal Candida colonization might be different 
before and after taking SGLT2 inhibitors [265]. 
The colonization of the vagina in prepubertal girls with Candida sp. is rare, as the low estrogen 
levels during childhood result in a rich anaerobic vaginal flora which inhibits Candida sp. Growth 
[266,267]. In a recent report, Atabek et al. [219] isolated Candida sp. in 39% of children with type 1 DM 
between 8–16 years in age. The subjects who had Candida sp. colonization and candidiasis were 
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considered all acute. C. albicans was found in 50% of all cases, followed by C. glabrata (36.6%), C. krusei 
(3.3%), and C. dubliniensis (3.3%). Patients with VVC had a greater mean HbA1c when compared to 
those without such infections, and the authors thus suggested that patients with DM should undergo 
periodic screening for genital candidiasis [219]. Similarly, Sonck et al. [268] studied the anogenital 
yeast flora of 166 diabetic girls of less than 15 years of age with vulvitis, revealing that 55% were 
colonized, mostly by C. albicans. 
Numerous studies have described the higher prevalence of asymptomatic vaginal colonization 
and symptomatic infection with Candida sp. in diabetic women, and some studies suggest pregnancy 
as an additional risk factor [254–256], although results are inconsistent [28,226]. 
Several studies have also shown that pregnancy and uncontrolled diabetes increase the infection 
risk. It is likely that reproductive hormone fluctuations during pregnancy and elevated glucose levels 
characteristic of diabetes provide the carbon needed for Candida overgrowth and infection. However, 
Sopian IL et al. [269] showed no relationship between diabetes and the occurrence of vaginal yeast 
infection in pregnant women, showing that there was no significant association between infection 
and age group, race, or education level [269]. In another report, Zheng et al. [254] studied the diversity 
of the vaginal fungal flora in healthy non-pregnant women, healthy pregnant women, women with 
gestational DM, and pregnant women with DM type 1 through an 18S rRNA gene clone library 
method[254]. Results showed that the most predominant vaginal fungal species belonged to the 
Candida and Saccharomyces genera. In a study of 251 women, Nowakowska et al. [270] demonstrated 
that the probability of vaginal mycosis was 4-fold greater in type 1 DM patients and nearly 2-fold 
greater in those with gestational DM when compared to healthy pregnant women. The report also 
highlighted the predominant role of poor glycemic control in the increased prevalence of vaginal 
candidiasis in pregnant women with type 1 DM [270]. In 2011, Masri et al. [271] determined the 
prevalence of Candida sp. in vaginal swabs of pregnant women from Serdang Hospital, Selangor, 
Malaysia, and their antifungal susceptibility. Results showed that 17.2% of the specimens were 
Candida sp., with C. albicans being the most common species detected (83.5%), followed by C. glabrata 
(16%) and C. famata (0.05%). All C. albicans and C. famata isolates were susceptible to fluconazole, 
whereas C. glabrata isolates had a dose-dependent susceptibility. The authors concluded that the first 
trimester, the second trimester, and DM were significant risk factors in patients for the vaginal 
candidiasis (p < 0.001). However, other studies noted that DM or impaired glucose tolerance during 
pregnancy was not connected with vaginal candidiasis [256]. Bassyouni et al. [242] explored the 
prevalence of VVC in diabetic women versus non-diabetic women and compared the ability of 
identified Candida sp. isolates to secrete PL and SAPs with the characterization of their genetic profile. 
The study involved 80 females with type 2 DM and 100 non-diabetics within the child-bearing period. 
Results revealed that VVC was significantly higher among the diabetic group (50%) versus the non-
diabetic group (20%), and C. albicans was the predominant species in both groups (75% in non-
diabetics and 50% in diabetics), followed by C. glabrata (20% in non-diabetics and 42.5% in diabetics). 
They also found that Candida sp. isolated from diabetics secreted higher quantities of proteinase than 
non-diabetics (87.7% and 65%, respectively), especially for C. albicans and C. glabrata, but non-
significant associations between any of the tested proteinase or PL genes and DM were detected. 
These results were—by some means—in agreement with the ones from other reports [243,244] that 
also detected C. parapsilosis and C. tropicalis in a group of diabetic women. Kumari et al. [248] detected 
poor PL production in the isolated Candida sp. (causing vulvovaginitis), of which 81.25% were C. 
parapsilosis, 30.43% C. albicans, and 18.75% C. glabrata. Moreover, insignificant differences in the 
expression of Candida sp. PLB1-2 genes and SAP1–SAP8 genes between diabetic and non-diabetic 
women were reported by Bassyouni and colleagues [242]. Still, they concluded that the higher 
prevalence of VVC among diabetics could be directly correlated to increased SAPs production. The 
discrepancies between the results of different reports may be due to changes in growth conditions 
and host factors that alter the gene expression qualitatively and quantitatively [59,247], although 
findings suggest that the expression of hydrolytic enzymes by Candida sp. is a multifactorial process 
in patients with DM and the hyperglycemia level is thus not the only implicated factor. 
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Lastly, VVC is intimately related to vaginal mucosae biofilms. Mikamo and colleagues studied 
the involvement of Candida’s complement receptor (ICAM-1) in the adhesion of C. albicans or C. 
glabrata to the genitourinary epithelial cells in high glucose states. Their results demonstrated that, 
while the adhesion of C. albicans to human vaginal epithelial cells VK2/E6E7 significantly increased 
in the high glucose, human vulvovaginal epidermal cells A431 did not. ICAM-1 expression was 
increased in VK2/E6E7 cultured in the high glucose, but the expression level in A431 was not 
elevated. These data suggested that ICAM-1 is a ligand in the adhesion of C. albicans to the vaginal 
epithelial cells in an environment with high glucose concentration. Moreover, both host immune 
dysfunction and the adjustment in epithelial cells were considered responsible for VVC in diabetic 
patients [272]. 
3.3. Urinary Tract Candidiasis 
Around 10% to 15% of in-hospital urinary tract infections (UTIs) are related to Candida sp. and 
the prevalence is still increasing [273]. Some predisposing factors such as DM, urinary retention, 
urinary stasis, renal transplantation, and hospitalization can increase the risk of candiduria. 
Specifically, DM has been known to cause severe complicated UTIs as a result of its various changes 
in the genitourinary system [274]. Since the 1980s, there has been a marked increase in opportunistic 
fungal infections involving the urinary tract, of which C. albicans is the most commonly isolated 
species, but NCAC sp. is now the majority in many countries worldwide [275,276]. Candiduria 
(presence of Candida sp. in urine) is an increasingly common finding in hospitalized patients [14], and 
subjects with DM are at a higher risk of developing fungal UTIs. Thus, reducing risk factors such as 
increasing glycemic control and the removal of urinary catheters can result in the remission of 
candiduria [273]. Physiopathology and etiology related to the occurrence of UTIs related to Candida 
sp. and DM are presented in Table 3. 
According to the results of the Falahati et al. [277] study, there were significant associations 
between candiduria and the female gender, high fasting blood sugar and urine glucose, uncontrolled 
diabetes (HbA1c ≥ 8), and acidic urine pH (p < 0.05). Causative agents were identified as C. glabrata 
(n = 19, 50%), C. albicans (n = 12, 31.6%), C. krusei (n = 4, 10.5%), C. tropicalis (n = 2, 5.3%), and C. kefyr 
(n = 1, 2.6%). The study concluded that when considering the high incidence rate of candiduria in 
diabetic patients, the control of diabetes, predisposing factors, and causal relationships between 
diabetes and candiduria should be highlighted [277]. In a 2018 study, Esmailzadeh et al. [276] 
evaluated candiduria among type 2 diabetic patients. Indeed, the results showed that the rate of 
candiduria was relatively high in type 2 diabetic patients and they were also suffering from a lack of 
proper blood glucose control. Although the frequency of NCAC sp. was not significantly higher than 
C. albicans, they obtained more from those with symptomatic candiduria [276]. In a cross-sectional 
study, Yismaw et al. [273] determined the fungal causative agents of UTIs in asymptomatic and 
symptomatic diabetic patients and associated risk factors. Significant candiduria was detected in 7.5% 
and 17.1% of asymptomatic and symptomatic type 2 diabetic patients, respectively. Among the 
isolated Candida sp., 84.2% was observed in the asymptomatic diabetic patients and the remaining 
15.8% in symptomatic patients. Rizzi and Trevisan studied the prevalence and significance of UTIs 
and genital infections (GI) in diabetes and the effects of sodium glucose cotransporter 2 (SGLT-2) 
inhibitors on these complications. Results presented that diabetic patients are at high risk of UTIs and 
of GIs. The authors concluded that only GIs were associated with poor glycemic control. Although 
patients treated with SGLT-2 inhibitors have an increased 3–5 fold risk of GIs, proper medical 
education may reduce this risk [278]. 
Diabetes mellitus, indwelling bladder catheter, sex (female), and the use of antibacterial agents 
have been found as the risk factors identified for both C. glabrata and C. albicans candiduria[275], as 
previously reported [27,279]. Emphysematous cystitis, which almost exclusively occurs in diabetic 
patients, is rare and is seldom the result of a fungal infection [280,281]. This condition is associated 
with a gas formation that may present itself as cystitis, pyelitis, or pyelonephritis. Uncontrolled DM 
is a major risk factor for this type of infection, as it provides a favorable microenvironment in which 
the gas-forming organisms can grow [282,283]. Alansari et al. [284] reported a case in which a patient 
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with uncontrolled DM was diagnosed with emphysematous pyelitis by C. tropicalis, while Wang et 
al.[285] also reported the case of a 53-year-old male patient with fungus ball and emphysematous 
cystitis caused concurrently by C. tropicalis. The predisposing factors were DM and usage of broad-
spectrum antibiotics. Garg et al.[286], in a one-year prospective single center study at Dayanand 
Medical College and Hospital, observed 151 diabetic and non-diabetic female patients diagnosed 
with UTIs. Uncontrolled diabetes was more commonly associated with severe UTIs like 
pyelonephritis and emphysematous pyelonephritis. 
Table 3. Physiopathology and etiology related to the occurrence of urinary tract infections and 
systemic candidiasis in diabetics. 
Condition Physiopathology Reference(s) 
Uncontrolled 
hyperglycemia (high 
HbA1c) 
and  
high glucose levels in 
urinary tract  (UT) 
mucosae or blood 
- Favorable microenvironment for the gas-forming 
organisms, such as Candida sp., to grow 
[282,283] 
Gender 
-An association between candiduria and being 
female 
[27,273,279] 
Drugs 
-SGLT2 inhibitors (e.g., dapagliflozin, canagliflozin, 
tofogliflozin) administration leads to a greater 
susceptibility to urinary tract infection (UTI)  
-Association with a persistent increase in urine 
glucose concentration 
[287] 
Escherichia coli was the most frequently isolated species in both groups, followed by Klebsiella, 
Pseudomonas, and Candida sp., and the latter was only isolated from the diabetic population. 
Tumbarello et al.[288] identified DM and urinary catheterization as features that are specifically 
associated with biofilm-forming Candida sp. bloodstream infections. Later, Vaidyanathan et al. [281] 
related a case of a 58-year-old diabetic paraplegic male with a long-term indwelling urethral catheter 
that developed a catheter block. Results showed an E. coli and C. albicans co-infection and HbA1c 
(glycosylated haemoglobin) was 111 mmol/mol, which is associated with uncontrolled DM. C. 
albicans later disseminated into the bloodstream through the damaged bladder and the urethral 
mucosa. Moreover, those isolates formed consistently high levels of biofilm formation in vitro and a 
resistance to voriconazole was also detected [281]. In another report, Suzuki et al. [287] investigated 
the relationship between UTIs and glucosuria, observing the effect of glucosuria induced by sodium-
glucose cotransporter 2 (SGLT2) inhibitors on the progression of UTIs in mice. The results showed 
that in mice treated with dapagliflozin and canagliflozin (not tofogliflozin), the amount of C. albicans 
colony forming units (CFU) in kidneys increased in accordance with both treatment duration and 
dosage. The urine glucose concentration (UGC) significantly increased up to 12 (tofogliflozin) to 24 h 
(dapagliflozin and canagliflozin) after SGLT2 administration, indicating that a greater susceptibility 
to UTIs is associated with a persistent increase in UGC [287]. 
3.4. Systemic Candidiasis 
It is recognized that DM predisposes one to systemic candidiasis for several factors [289]. Among 
these factors, the most important are the microvascular disease progression, the low host defense 
mechanisms, and the diabetic vasculopathy, which exacerbates hypoperfusion and hyperglycemia 
and may lead to neutrophil and lymphocyte dysfunction with impaired opsonization [11,42,298–
307,290,308–317,291,318–322,292–297]. Catheter-associated candiduria is a common clinical finding 
in hospitalized patients, especially in intensive care units [295], and is intimately related to biofilms. 
Padawer et al. [295] studied demographic and clinical data at an Israeli hospital between 2011 and 
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2013 on the prevalence of Candida sp. in catheterized in-patients and the medical interventions 
provided to these patients. Their results showed that candiduria was observed in 146 catheterized in-
patients out of the 1408 evaluated and was directly associated with DM. C. albicans was present in 
69.1% of the subjects, followed by C. parapsilosis (9.58%), C. krusei (7.53%), C. tropicalis (6.16%), C. 
glabrata (4.79%), and other species (2.73%). DM was found to be a significant risk factor of infection 
by Candida sp. In another report, Padawer et al.[295] concluded that Candida sp. was the second 
leading pathogen causing catheter-associated urinary tract infections or asymptomatic colonization. 
Previously, Tambyah et al. [296], Makin and Tambyah [297], and Sievert et al. [298] found similar 
results. 
Muskett et al. [299] performed a systematic review to identify the most prevalent risk factors, 
looking at published analyses, risk prediction models, and clinical decision rules for invasive fungal 
disease (IFD) in critically ill adult patients. The authors found studies that had a significant 
association of DM and IFD on both univariable and multivariable analyses. Paphitou and 
colleagues[300] established that patients with any combination of DM, new onset hemodialysis, use 
of total parenteral nutrition, or receipt of broad-spectrum antibiotics had an invasive candidiasis rate 
of 16.6% compared to a 5.1% rate in patients lacking these characteristics (p = 0.001). Also, 
Michalopuolos et al.[301], in a univariate regression analysis study between 1997 and 2002, confirmed 
that DM is a significant candidemia-associated factor and an independent candidemia predictor. C. 
albicans (70%), C. parapsilosis (10%), C. glabrata (6.7%), C. tropicalis (6.7%), and C. krusei (6.7%) were 
isolated in patients with candidemia. C. albicans was simultaneously isolated from blood (89.5%) and 
the central venous catheter tip. Among other factors, the authors found that DM was associated with 
a high 30-day mortality in candidemia. Candidemia due to C. parapsilosis was associated with high 
rates of survival[11], probably due to the fact that adherence and protein secretion do not correlate 
with strain pathogenicity in this species as opposed to the other Candida sp., as had been 
discussed[323]. Another retrospective study from 2007 to 2015 of candidemia in hospitalized adults 
was performed by Khatib et al. Most of the isolates (97.5%) were C. albicans. C. glabrata was more common 
in diabetics (52.9% vs. 32.0% in non-diabetics; p = 0.004) and in abdominal sources. The findings suggested 
possible species-related differences in colonization dynamics or pathogenicity [324]. 
Abad et al. [304] carried out a different study to investigate the susceptibilities of clinical 
fluconazole-resistant and fluconazole-susceptible dose-dependent to caspofungin of 207 Candida sp. 
in Iranian patients. Results showed that only 9.7% of the isolates were non-sensitive to caspofungin 
and that these isolates were observed in cancer, DM, and AIDS patients [304]. Wu et al. [305] 
investigated 238 candidemia hospitalized patients between 2009 and 2011 so as to study the incidence 
rates of candidemia and identify the differences in risk factors of patients with C. albicans and NCACs 
and with C. guilliermondii and non-C. guilliermondii candidemia. DM was identified as a significant 
risk factor in patients with candidemia due to C. albicans (35.2%) compared to candidemia related to 
NCACs (13.2%). Although C. guilliermondii is an uncommon cause of candidemia, even in 
immunocompromised hosts[306–311], it was also found to occur in a significant amount of the 
hospitalized patients. Over the three year period, the percentage of candidemia due to C. albicans 
decreased, while the percentage of candidemia due to C. parapsilosis and C. guilliermondii increased 
in more than 80% of all candidemia cases in 2011 [305]. 
Candida sp. bloodstream infections (CBSI) are the fourth leading cause of nosocomial 
bloodstream infections in the United States [316,318,325]. CBSIs occur in up to 10% of all bloodstream 
infections in hospitalized patients [313–315], and the mortality rate is about 40% [316,317]. Normally, 
this mortality is higher than in bloodstream infections involving bacteria [326,327]. Risk factors for 
CBSIs include critically ill patients in intensive care units, DM, immunosuppressive states, 
mechanical ventilation, neutropenia, recent surgical procedures, and prematurity [315,318,319]. In a 
study by Tumbarello and colleagues [328], it was found that DM is an independent predictor of 
biofilm-forming Candida sp. CBSIs. The use of total parenteral nutrition, hospital mortality, post-CBSI 
hospital length of stay (LOS), and the costs of antifungal therapy were all significantly greater among 
patients infected by biofilm-forming isolates when compared to those infected by non-biofilm-
forming isolates. It was concluded that biofilm-forming CBSI was significantly related with a high 
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risk of death compared to non-biofilm forming CBSI [328]. Corzo-Leon and colleagues [320] 
investigated the clinical and epidemiologic characteristics of patients with CBSI in two tertiary care 
reference medical institutions in Mexico City. Their results showed that CBSIs represented 3.8% of 
nosocomial bloodstream infections and C. albicans was the predominant species (46%), followed by 
C. tropicalis (26%). C. glabrata was isolated from 50% of patients with diabetes and elderly patients. 
Nucci et al. [321] published a paper reporting an incidence of 1.18 episodes of candidemia per 1000 
admissions. C. albicans, C. tropicalis, and C. parapsilosis were isolated in 80% of cases and DM was also 
found in 11% of the total cases. Gupta et al.[322] reviewed the influence of C. glabrata candidemia in 
intensive care unit (ICU) patients between 2006 and 2010. Results showed that this species was the 
third most isolated, and DM was a risk factor among 50% of the total cases. Also, urine was the most 
common source of C. glabrata candidemia, while the overall mortality rate was 53.8% [322]. In another 
report, Wang et al. [42] observed no differences in the distribution of Candida sp. between elderly and 
young patients in China, but the resistance to fluconazole and voriconazole for NCAC in the first 
group was double the amount of the latter. Host-related risk factors included DM, mechanical 
ventilation, central vascular and urethral catheter placement, and were more common in elderly 
patients [42]. 
3.5. Other Candidiasis 
Diabetic patients are highly predisposed to cutaneous fungal infections due to the higher blood 
sugar levels. These infections are frequently characterized by thick biofilms, and sometimes the use 
of medical devices to drain these lesions is mandatory. Foot infection (tinea pedis and toenail 
onychomycosis) is particularly important to diabetic individuals due to the high incidence of diabetic 
foot in these patients [329,330]. The most significant Candida sp. causing onychomycosis are C. albicans 
and C. parapsilosis and it is known that DM patients have a high rate of tinea pedis and 
onychomycosis. Thus, this infection is now considered to be a predictor of diabetic foot syndrome 
[331]. The predisposing factors for tinea pedis et unguium are presented in Table 4.  
Diabetic foot ulcers are a serious cause of diagnostic and therapeutic concern, and Non-albicans 
Candida spp. with potential biofilm forming abilities are emerging as a predominant cause of this 
problematic condition. Indeed, in a recent study, the prevalence of different Candida sp. was 
identified as C. tropicalis (34.6%), C. albicans (29.3%), C. krusei (16.0%), C. parapsilosis (10.6%), and C. 
glabrata (9.33%)[332]. In order to find the frequency of fungal infections among cutaneous lesions of 
diabetic patients and to investigate azole antifungal agent susceptibility of the isolates, Raiesi et al. 
[333] studied type 1 and type 2 DM patients with foot ulcers (38.5%) and with skin and nail lesions 
(61.5%). Results showed that 24.5% had fungal infections and were at a higher frequency in patients 
with skin and nail lesions (28%) than in foot ulcers (19.1%). C. albicans and Aspergillus flavus were the 
most common species isolated, and a high prevalence of fluconazole-resistant Candida sp., 
particularly in diabetic foot ulcers, was determined [333]. 
Table 4. Physiopathology and etiology related to the occurrence of nail fungal diseases linked to 
Candida sp. in diabetics. 
Condition Physiopathology Reference(s) 
Uncontrolled hyperglycemia 
(high HbA1c) 
and  
high glucose levels in vaginal 
mucosae 
-Circulatory disorders affecting the lower 
extremities (peripheral circulation), 
peripheral neuropathy, and retinopathy 
- Nail thickness is associated with an 
elevated HbA1c value 
- Diabetics using hemodialysis exhibit a 
higher probability of onychomycosis  
[329,330,334–
338] 
Duration of DM 
-More time leads to a higher probability 
of onychomycosis 
[336] 
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Gender 
Aging 
-Being male and being older are directly 
associated with onychomycosis in 
diabetics 
[331] 
[336] 
Diabetics with onychomycosis have a greater risk of having a diabetic foot ulcer 
[336,337,339,340], as confirmed by numerous studies. In Germany, Eckhard and colleagues [337] 
found that out of 95 patients with type 1 DM, 84.6% had a fungal infection. The most frequent Candida 
sp. found were C. albicans, C. parapsilosis, and C. guilliermondii, followed by C. lipolytica, C. catenulate, 
and C. famata. In another study conducted at the Umm Al-Qura University, Makkah, Saudi Arabia 
from June 2011 to June 2012, the antimicrobial susceptibility of the most common bacterial and fungal 
infections among infected diabetic patients (foot infections) was determined. All Candida sp. showed 
susceptibility to amphotericin B, econazole, fluconazole, ketoconazole, and nystatin (100% each)[340]. 
Cases with Candida sp. co-infection were also observed in patients with fungal nail infections—both 
cutaneous and nail infections [337]. Lugo-Somolinos et al.[334] performed a cross-sectional study in 
Japan and revealed that 51.3% of patients with DM had onychomycosis of the toenails. In this 
particular case, C. albicans was more prevalent in the control group (24% vs. 15% in the DM patients) 
and nail thickness was significantly associated with an elevated HbA1c value [334]. Gupta et al. [341] 
reported that there was a 2.77-fold greater risk for diabetic subjects than for healthy individuals to 
have toenail onychomycosis. In the same year, a previous study in Taiwan reported that 60.5% of 
onychomycosis was caused by dermatophytes, 31.5% by Candida sp., and 8% by non-dermatophyte 
molds [342]. A total of 20 patients with onychomycosis had concomitant DM. Regarding gender, in 
diabetic males, the most common pathogens were dermatophytes (58.3%), while in diabetic females, 
Candida sp. was more prevalent (87.5%)[342]. However, on the contrary, Dogra and colleagues found 
that in Indian diabetics, yeasts were the most common isolate (48.1%), followed by dermatophytes 
(37%) and non-dermatophyte molds (14.8%)[336]. The authors concluded that diabetics had a 2.5 
times greater probability of having onychomycosis when compared to the controls [336]. Chang et 
al.[331] studied 1245 Taiwanese patients with DM. Among them, 30.76% were reported to suffer from 
onychomycosis. In this investigation, the diagnosis of onychomycosis was limited to a general 
histopathologic examination (KOH stain) of the toenails. Therefore, the patients may have been 
affected by Candida sp. and by other fungi. Another study performed by Pierard et al.[335] 
investigated onychomycosis in 100 DM patients on chronic hemodialysis, showing that 39% of 
participants had a nail disease. Candida sp. was the second most prevalent pathogen (15%), and the 
authors concluded that diabetics on hemodialysis had about an 88% greater probability of acquiring 
onychomycosis than non-diabetics[335]. Another report by Wijesuriya and colleagues[338] described 
the etiological agents causing superficial fungal foot infections (SFFI) in patients with type 2 DM for 
one year. Their results demonstrated that 295 patients had SFFI and that, among patients with 
diabetes, more than 10 showed a prevalence of SFFI of 98%. Aspergillus niger was the most common 
pathogen, followed by C. albicans. Aging, gender, the duration of diabetes, and less-controlled 
glycemic levels were significantly associated with SFFIs[338]. 
A 2018 study explored the differential expression of toll-like receptor 2 (TLR2) and interleukin 
(IL)-8 secretion by keratinocytes in diabetic patients when challenged with C. albicans. Wang et al. 
[343] determined that the expression levels of both TLR2 and IL-8 increased and then decreased in 
the control and the diabetic groups, but in different dynamics. The observations revealed that TLR2 
and IL-8 act on the keratinocytes interacting with C. albicans, and high glucose status can distress the 
function of HaCaT cells by reducing the secretion of IL-8 and TLR2. The study clearly supports the 
immunosuppression state that diabetic patients live in [343]. 
Adherence to the vascular endothelium, neutrophil chemotaxis, phagocytosis and opsonization, 
intracellular bactericidal activity, and cell-mediated immunity are all decreased in DM patients with 
hyperglycemia [344,345]. Regarding this matter, Souza et al. [346] treated diabetic rats with 
aminoguanidine (AMG, an inhibitor of protein glycation) and evaluated neutrophil reactive oxygen 
species (ROS) generation and C. albicans killing ability in order to evaluate the effects of 
hyperglycemia and the glycation of proteins on the NOX2 (phagocyte NADPH oxidase) activity of 
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neutrophils and its implications for cellular physiology. The authors indicated that AMG increased 
the NOX2 response and microbicidal activity by neutrophils of the diabetic status. AMG seems to be 
a promising therapeutic answer for these patients [346]. 
In another interesting recent in vivo report, the interference of diabetic conditions in diabetic 
mice and the relation to the progress of C. albicans infection and anti-inflammatory response was 
evaluated. Compared to non-diabetic mice, diabetic mice indicated a significantly lower density of 
F4/80 and M2 macrophages, higher fungal burden, and deficiency in cytokine responses. C. albicans 
also increased tissue injury, highlighting significant deviations in diabetic animal responses to C. 
albicans infection that may be critical to the pathophysiological processes supporting cutaneous 
candidiasis in diabetic patients [347]. 
Several other pathologies related to Candida sp. have also been linked to a DM predisposition. 
Researchers often recognize the importance of DM in the development of the pathology due to 
immunosuppression issues [348]. The reports are summarized in Table 5. 
Table 5. Physiopathology and etiology related to the occurrence of other diseases linked to Candida 
sp. in diabetics. 
Condition Physiopathology 
Candida sp. 
Found in 
the Study  
Reference(s) 
Arterial infection 
-Direct invasion or haematogenous spread 
of Candida sp. to the vessels wall (less 
common): 
a. infection of a pre-existing aneurysm 
(most possible from atherosclerotic) with 
fungi after an episode of candidemia  
b. contained fungal infection of the arterial 
wall (linked mostly to intravenous drug 
abuse). 
C. albicans 
C. tropicalis 
C. 
parapsilosis 
Other 
Candida sp.  
(not 
specified) 
[348–357] 
Endophthalmitis 
- Uncontrolled DM concomitant with other 
co-morbidities 
C. albicans [358] 
Cholecystitis 
- Uncontrolled DM concomitant with other 
co-morbidities 
C. famata [359] 
Skin abscesses 
- Uncontrolled DM concomitant with other 
co-morbidities 
C. albicans [360,361] 
Brain abscesses 
-Immunocompromised states and poorly-
controlled diabetes (the role of DM as an 
immunosuppressive condition in this 
particular case is uncertain) 
C. albicans 
C. 
parapsilosis 
C. tropicalis  
C. 
guilliermondi 
Other 
Candida sp.  
(not 
specified) 
[362–364] 
Fungal infections 
after liver 
transplantation 
- Chronically high blood sugar may be a 
predisposing factor (among other factors) 
C. albicans [365] 
Peritonitis 
- Uncontrolled DM concomitant with other 
co-morbidities 
C. 
haemulonii 
C. glabrata 
Other 
Candida sp.  
[366–368] 
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(not 
specified) 
Penile prosthesis 
Infections 
Other 
Candida sp. 
(not 
specified) 
[369–372] 
Balanitis C. albicans [373] 
Fournier’s gangrene 
Candida sp.  
(not 
specified) 
[374] 
Chronic obstructive 
pulmonary disease 
C. ciferrii [375] 
4. Diabetes Mellitus In Vivo Models 
Diabetes mellitus is a serious epidemic disease, and the research for new therapies is becoming 
critical. Thus, the correct choice of the animal models is of vital importance for the validity of the 
reported studies. 
In DM type 1, the choices range from chemical ablation of the pancreatic -cells to animals with 
spontaneously developing autoimmune diabetes. In DM type 2, the animal models can be both obese 
and non-obese animals with varying degrees of insulin resistance and beta cell failure [376]. The 
animal models (e.g., species, strain, gender, genetic) of DM type 1 and type 2 have diverse purposes, 
and the choice of a model depends on the purpose of the study (e.g., applied for pharmacological or 
genetics studies and understanding disease mechanisms)[376–381]. Table 6 summarizes the main 
animal models used in diabetes mellitus in vivo studies. 
Table 6. Main animal models used in diabetes mellitus studies[376]. 
Diabetes 
Mellitus 
Model/Induction Studies Features 
Type 1 Chemical induction 
 
High dose 
streptozotocin 
New formulations of insulin Hyperglicaemia model 
 Alloxan Transplantation 
Induced insulitis 
 
Multiple low dose 
streptozotocin 
Treatment to prevent β-cell 
death 
 Spontaneous autoimmune 
 NOD mice Understanding genetic 
mechanisms 
Autoimmune β-cell 
destruction 
 BB rats 
 LEW.1AR1/-iddm rats 
Treatment to prevent β-cell 
death or to manipulate 
autoimmune processes 
 Genetically Induced 
 AKITA rats* 
New formulations of insulin 
Transplantation 
Treatment to prevent ER 
stress 
β-cell destruction due 
to ER + Insulin 
dependent 
 Virally induction   
 Coxsackie B virus 
Study of potencial role of 
viruses in  
DM type 1 
Viral β-cell destruction  
Encephalomyocarditis 
virus 
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 Kilham rat virus 
  
 
Lymphocytic 
choriomeningitis virus 
(LCMV) under insulin 
promoter 
Type 2 Monogenic - obese models 
  
Obese-induced 
hyperglycemia 
 Lepob/ob mice 
Treatment to improve insulin 
resistance 
 
 Leprdb/db mice 
Treatment to improve β-cell 
resistance 
 KDF rats  
 Polygenic—obese models 
 KK mice 
Treatment to insulin 
resistance 
 OLEFT rat 
Treatment to improve β-cell 
function 
 NZO mice 
Some models show diabetic 
complications 
 TallyHO/Jng mice  
 NoncNZO10/|LtJ mice  
 Induced obesity 
 
High fat feeding (mice or 
rats) 
Treatment to insulin 
resistance 
 Nile grass rat 
Treatment to prevent diet-
induced obesity 
 Desert gerbil 
Treatment to improve β-cell 
function 
* can be also used as a DM type 2 model. 
5. Conclusions 
Diabetes mellitus is a severe metabolic chronic disease that is most prevalent in developed 
countries. The general immunocompromised state with an often-poor glucose control often leads to 
secondary diseases in DM individuals. The biofilm fungal infections in diabetic patients are 
recognized to be more complicated to treat than they are in healthy patients, especially if related to 
medical devices. Among the candidiasis, oral diseases are the most frequent infections that occur in 
DM patients, as well as VVC and, more seriously, systemic candidiasis. The reports of these cases 
and the results of the elected therapeutic are extremely important if we are to continue to treat these 
patients in the most effective manner. 
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